Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has completed treatment with EOW velaglucerase alfa through Week 51 of study HGT-GCB-087.~* Female patients of child bearing potential must agree to use a medically acceptable method of contraception at all times during the study.~* The patient, the patient's parent(s)or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee(IRB/IEC)~* The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator.~Exclusion Criteria:~* The patient has received treatment with any investigational drug, other than velaglucerase alfa, or investigational device within 30 days prior to study entry; such use during the study is not permitted.~* The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study.~* The patient has a significant comorbidity, as determined by the Investigator that might affect study data or confound the study results.~* The patient is unable to comply with the protocol as determined by the Investigator.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- velaglucerase alfa (Type: EXPERIMENTAL): 15 to 60 U/kg, EOW via intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).